肺康复对间质性肺疾病(含冠状病毒病)的有效性:系统综述与荟萃分析
该系统综述与荟萃分析纳入11项随机对照试验共637例间质性肺疾病患者,评估肺康复对肺功能、运动能力、健康相关生活质量及呼吸困难的影响。结果显示肺康复可显著改善用力肺活量、6分钟步行距离和健康相关生活质量,但对呼吸困难改善未达统计学意义。作者认为肺康复可作为改善该类患者功能能力和生活质量的有效治疗策略。
要点
- 肺康复可显著改善间质性肺疾病患者用力肺活量(合并效应量0.37)。
- 肺康复可显著提高6分钟步行距离(合并效应量44.55)。
- 肺康复可显著改善健康相关生活质量(合并效应量0.52),呼吸困难改善未达统计学意义。
核心结论
- 肺康复可考虑作为间质性肺疾病患者改善功能能力和生活质量的有效治疗策略,尽管针对COVID-19患者的具体证据尚在出现。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE、SPORTDiscus、Cochrane Library、Web of Science和MedRxiv自建库至2020年11月。
- 纳入11项随机对照试验,共637例间质性肺疾病患者,采用Cochrane RoB 2.0工具评估偏倚风险。
主要发现
- 肺康复与用力肺活量的合并效应量为0.37(95%CI 0.02-0.71)。
- 肺康复与6分钟步行距离的合并效应量为44.55(95%CI 32.46-56.64)。
- 肺康复与健康相关生活质量的合并效应量为0.52(95%CI 0.22-0.82)。
- 肺康复与呼吸困难的合并效应量为0.39(95%CI -0.08至0.87),未达统计学意义。
- 结合临床改善解读,肺康复使预测用力肺活量增加5.5%,6分钟步行距离改善44.55米,健康相关生活质量较基线改善3.9分。
关键数值与推荐
- 纳入研究评估肺康复对用力肺活量、6分钟步行距离、健康相关生活质量和呼吸困难的影响。
- 敏感性分析结果与主要分析相似。
临床怎么用
- 对间质性肺疾病患者可考虑实施肺康复以改善肺功能、运动能力和健康相关生活质量。
- 呼吸困难改善证据尚不充分,临床决策需结合患者具体情况。
局限性
- 针对COVID-19患者肺康复的具体证据尚有限,结论主要基于间质性肺疾病总体人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A meta-analysis of randomized controlled trials (RCTs) was conducted to determine the effect of pulmonary rehabilitation on functional capacity and quality of life in interstitial lung diseases, including those caused by coronaviruses. DATA SOURCES: MEDLINE, EMBASE, SPORTDiscus, Cochrane Library, Web of Science, and MedRxiv from inception to November 2020 were searched to identify documents. STUDY SELECTION: Publications investigating the effect of pulmonary rehabilitation on lung function (forced vital capacity [FVC]), exercise capacity (6-minute walk distance [6MWD]), health related quality of life (HRQOL), and dyspnea were searched. DATA EXTRACTION: The data were extracted into predesigned data extraction tables. Risk of bias was evaluated with the Cochrane Risk of Bias tool (RoB 2.0). DATA SYNTHESIS: A total of 11 RCTs with 637 interstitial lung disease patients were eligible for analyses. The pooled effect sizes of the association for pulmonary rehabilitation were 0.37 (95% confidence interval [CI], 0.02-0.71) for FVC, 44.55 (95% CI, 32.46-56.64) for 6MWD, 0.52 (95% CI, 0.22-0.82) for HRQOL, and 0.39 (95% CI, -0.08 to 0.87) for dyspnea. After translating these findings considering clinical improvements, pulmonary rehabilitation intervention increased predicted FVC by 5.5%, the 6MWD test improved by 44.55 m, and HRQOL improved by 3.9 points compared with baseline values. Results remained similar in sensitivity analyses. CONCLUSIONS: Although specific evidence for pulmonary rehabilitation of coronavirus disease 2019 patients has emerged, our data support that interstitial lung disease rehabilitation could be considered as an effective therapeutic strategy to improve the functional capacity and quality of life in this group of patients.
引用
- Reina-Gutiérrez S, Torres-Costoso A, Martínez-Vizcaíno V, et al. Effectiveness of Pulmonary Rehabilitation in Interstitial Lung Disease, Including Coronavirus Diseases: A Systematic Review and Meta-analysis. Arch Phys Med Rehabil. 2021. PMID: 33932361. doi:10.1016/j.apmr.2021.03.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。